Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting.

@article{Flannery2006EfficacyAS,
  title={Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting.},
  author={Michael T. Flannery and Joe Wesley Ramsdell and Alan Ranhosky and Giora Davidai and Gary E. Ruoff},
  journal={Current medical research and opinion},
  year={2006},
  volume={22 4},
  pages={
          721-30
        }
}
OBJECTIVE This study evaluated the efficacy and safety of the alpha(1A)/alpha(1D) subtype-selective blocker tamsulosin for the increasingly common treatment of benign prostatic hyperplasia (BPH) in the primary care setting. METHODS A total of 493 men (age > or = 45 years), 99.6% of whom had moderate or severe BPH at baseline, were given tamsulosin 0.4 mg/day in a multicenter, open-label study conducted over 45 days by 42 primary care physicians and two urologists. RESULTS Mean American… CONTINUE READING